These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 32258210)

  • 1. Defining the Optimal FVIII Transgene for Placental Cell-Based Gene Therapy to Treat Hemophilia A.
    El-Akabawy N; Rodriguez M; Ramamurthy R; Rabah A; Trevisan B; Morsi A; George S; Shields J; Meares D; Farland A; Atala A; Doering CB; Spencer HT; Porada CD; Almeida-Porada G
    Mol Ther Methods Clin Dev; 2020 Jun; 17():465-477. PubMed ID: 32258210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of different gene addition strategies to modify placental derived-mesenchymal stromal cells to produce FVIII.
    Ramamurthy RM; Rodriguez M; Ainsworth HC; Shields J; Meares D; Bishop C; Farland A; Langefeld CD; Atala A; Doering CB; Spencer HT; Porada CD; Almeida-Porada G
    Front Immunol; 2022; 13():954984. PubMed ID: 36591257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical Development of a Hematopoietic Stem and Progenitor Cell Bioengineered Factor VIII Lentiviral Vector Gene Therapy for Hemophilia A.
    Doering CB; Denning G; Shields JE; Fine EJ; Parker ET; Srivastava A; Lollar P; Spencer HT
    Hum Gene Ther; 2018 Oct; 29(10):1183-1201. PubMed ID: 30160169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of an optimized lentiviral vector encoding a high-expression factor VIII transgene for gene therapy of hemophilia A.
    Johnston JM; Denning G; Doering CB; Spencer HT
    Gene Ther; 2013 Jun; 20(6):607-15. PubMed ID: 22996197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Shear Stress on Production of FVIII and vWF in a Cell-Based Therapeutic for Hemophilia A.
    Trevisan B; Morsi A; Aleman J; Rodriguez M; Shields J; Meares D; Farland AM; Doering CB; Spencer HT; Atala A; Skardal A; Porada CD; Almeida-Porada G
    Front Bioeng Biotechnol; 2021; 9():639070. PubMed ID: 33732691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hemophilia A gene therapy via intraosseous delivery of factor VIII-lentiviral vectors.
    Miao CH
    Thromb J; 2016; 14(Suppl 1):41. PubMed ID: 27766066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigating Optimal Autologous Cellular Platforms for Prenatal or Perinatal Factor VIII Delivery to Treat Hemophilia A.
    Stem C; Rodman C; Ramamurthy RM; George S; Meares D; Farland A; Atala A; Doering CB; Spencer HT; Porada CD; Almeida-Porada G
    Front Cell Dev Biol; 2021; 9():678117. PubMed ID: 34447745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficient production of human FVIII in hemophilic mice using lentiviral vectors.
    Kootstra NA; Matsumura R; Verma IM
    Mol Ther; 2003 May; 7(5 Pt 1):623-31. PubMed ID: 12718905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Target-Cell-Directed Bioengineering Approaches for Gene Therapy of Hemophilia A.
    Brown HC; Zakas PM; George SN; Parker ET; Spencer HT; Doering CB
    Mol Ther Methods Clin Dev; 2018 Jun; 9():57-69. PubMed ID: 29552578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hematopoietic stem cells encoding porcine factor VIII induce pro-coagulant activity in hemophilia A mice with pre-existing factor VIII immunity.
    Doering CB; Gangadharan B; Dukart HZ; Spencer HT
    Mol Ther; 2007 Jun; 15(6):1093-9. PubMed ID: 17387335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minimal Essential Human Factor VIII Alterations Enhance Secretion and Gene Therapy Efficiency.
    Cao W; Dong B; Horling F; Firrman JA; Lengler J; Klugmann M; de la Rosa M; Wu W; Wang Q; Wei H; Moore AR; Roberts SA; Booth CJ; Hoellriegl W; Li D; Konkle B; Miao C; Reipert BM; Scheiflinger F; Rottensteiner H; Xiao W
    Mol Ther Methods Clin Dev; 2020 Dec; 19():486-495. PubMed ID: 33313336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterogeneity of the immune response to adenovirus-mediated factor VIII gene therapy in different inbred hemophilic mouse strains.
    Rawle FE; Shi CX; Brown B; McKinven A; Tinlin S; Graham FL; Hough C; Lillicrap D
    J Gene Med; 2004 Dec; 6(12):1358-68. PubMed ID: 15493040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Enhancing effect of porcine coagulation factor VIII A1 and A3 domains on secretion of post-translationally spliced human/porcine hybrid coagulation factor VIII].
    Zhu FX; Liu ZL; Qu HG; Chi XY
    Sheng Li Xue Bao; 2010 Aug; 62(4):373-81. PubMed ID: 20717639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The canine factor VIII 3'-untranslated region and a concatemeric hepatocyte nuclear factor 1 regulatory element enhance factor VIII transgene expression in vivo.
    Notley C; Killoran A; Cameron C; Wynd K; Hough C; Lillicrap D
    Hum Gene Ther; 2002 Sep; 13(13):1583-93. PubMed ID: 12228013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ex vivo gene therapy for hemophilia A that enhances safe delivery and sustained in vivo factor VIII expression from lentivirally engineered endothelial progenitors.
    Matsui H; Shibata M; Brown B; Labelle A; Hegadorn C; Andrews C; Hebbel RP; Galipeau J; Hough C; Lillicrap D
    Stem Cells; 2007 Oct; 25(10):2660-9. PubMed ID: 17615271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained expansion and transgene expression of coagulation factor VIII-transduced cord blood-derived endothelial progenitor cells.
    Herder C; Tonn T; Oostendorp R; Becker S; Keller U; Peschel C; Grez M; Seifried E
    Arterioscler Thromb Vasc Biol; 2003 Dec; 23(12):2266-72. PubMed ID: 14551158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical assessment of an optimized AAV-FVIII vector in mice and non-human primates for the treatment of hemophilia A.
    Elkouby L; Armour SM; Toso R; DiPietro M; Davidson RJ; Nguyen GN; Willet M; Kutza S; Silverberg J; Frick J; Crosariol M; Wang Y; Wang C; High KA; Sabatino DE; Anguela XM
    Mol Ther Methods Clin Dev; 2022 Mar; 24():20-29. PubMed ID: 34977269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of therapeutic levels of factor VIII in hemophilia A mice using a novel adeno/adeno-associated hybrid virus.
    Gnatenko DV; Wu Y; Jesty J; Damon AL; Hearing P; Bahou WF
    Thromb Haemost; 2004 Aug; 92(2):317-27. PubMed ID: 15269828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of FVIII immunity on hepatocyte and hematopoietic stem cell-directed gene therapy of murine hemophilia A.
    Lytle AM; Brown HC; Paik NY; Knight KA; Wright JF; Spencer HT; Doering CB
    Mol Ther Methods Clin Dev; 2016; 3():15056. PubMed ID: 26909355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential for cellular stress response to hepatic factor VIII expression from AAV vector.
    Zolotukhin I; Markusic DM; Palaschak B; Hoffman BE; Srikanthan MA; Herzog RW
    Mol Ther Methods Clin Dev; 2016; 3():16063. PubMed ID: 27738644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.